Sanofi Ventures — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
Abcuro is a clinical-stage biopharmaceutical company developing ulviprubart, a monoclonal antibody that selectively depletes highly cytotoxic T cells by targeting the KLRG1 receptor.
BiotechHealthtechNewton, US
John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Ryan Berry(Director)Donald McCarthy(Director)John Edwards(Director)Yajun Xu(Director)
Board seatJason P. Hafler· per SEC Form D
BiotechSan Diego, US
JeenJoo Kang(Director)Robert Tjian(Director)Alain Baron(Executive Officer, Director)Marcus Boehm(Executive Officer)Andrew Schwab(Director)
Board seatJason P. Hafler· per SEC Form D · $77.5M raise · filed Sep 2020
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.